Phio Pharmaceuticals Corp. PHIO
Phio Pharmaceuticals Corp. ("Phio," "we," "our" or the "Company") is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment and a single reportable segment.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $21.0K | $138.0K | $15.0K | $19.0K |
| R&D | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M |
| SG&A | $4.6M | $3.7M | $4.4M | $4.5M | $4.6M | $5.1M | $4.7M | $3.2M | $4.0M | $3.6M |
| Total operating expenses | $9.2M | $7.4M | $10.8M | $11.5M | $13.5M | $8.8M | $9.0M | $7.5M | $14.1M | $9.0M |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M | -$8.8M | -$9.0M | -$7.4M | -$14.1M | -$9.0M |
| Interest expense | — | $231.0K | $8.0K | — | — | — | — | — | — | — |
| Pre-tax income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M | -$8.8M | -$8.9M | -$7.4M | -$14.1M | -$9.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.6M | $0 |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M | -$8.8M | -$8.9M | -$7.4M | -$12.5M | -$9.0M |
| EPS, basic | -1.45 | -9.08 | -46.76 | -10.10 | -12.43 | — | — | — | — | — |
| EPS, diluted | — | -9.08 | -46.76 | -10.10 | -12.43 | -1.92 | -19.33 | -57.46 | -5.52 | -16.41 |
| Shares, diluted (wtd. avg.) | $6.0M | $787.5K | $231.5K | $1.1M | $1.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $21.0M | $5.4M | $8.5M | $11.8M | $24.1M | $14.3M | $7.0M | $14.9M | $3.6M | $13.0M |
| Total current assets | $21.5M | $5.7M | $9.3M | $12.4M | $24.7M | $15.2M | $7.3M | $15.2M | $3.8M | $13.1M |
| Property, plant and equipment | $11.0K | $2.0K | $6.0K | $183.0K | $133.0K | $157.0K | $210.0K | $172.0K | $248.0K | $114.0K |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M | $15.7M | $8.0M | $15.3M | $4.1M | $13.4M |
| Accounts payable | $435.0K | $253.0K | $657.0K | $779.0K | $283.0K | $728.0K | $809.0K | $550.0K | $511.0K | $917.0K |
| Total current liabilities | — | $1.0M | $1.6M | $1.9M | $3.1M | $2.2M | $1.9M | $1.7M | $2.3M | $2.5M |
| Long-term debt | — | — | — | — | $0 | $231.0K | $0 | — | — | — |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M | $2.7M | $2.3M | $1.7M | — | — |
| Retained earnings | -$155.1M | -$146.4M | -$139.2M | -$128.4M | -$116.9M | -$103.6M | -$94.8M | -$85.9M | -$78.6M | -$66.1M |
| Total equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M | $13.0M | $5.7M | $13.6M | $1.8M | $10.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M | -$8.8M | -$8.6M | -$7.5M | -$9.5M | -$7.8M |
| Depreciation and amortisation | $3.0K | $2.0K | $56.0K | $71.0K | $75.0K | $72.0K | $67.0K | $81.0K | $70.0K | $53.0K |
| Stock-based compensation | $481.0K | $147.0K | $303.0K | $414.0K | $480.0K | $136.0K | $300.0K | $282.0K | $314.0K | $756.0K |
| Capital expenditure | $12.0K | $1.0K | $5.0K | $121.0K | $51.0K | $19.0K | $72.0K | $5.0K | $203.0K | $4.0K |
| Investing cash flow | -$12.0K | $8.0K | -$5.0K | -$121.0K | -$51.0K | -$19.0K | -$72.0K | -$5.0K | -$103.0K | $5.3M |
| Financing cash flow | $23.6M | $4.0M | $7.4M | -$26.0K | $21.7M | $16.1M | $772.0K | $18.8M | $292.0K | $10.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-027997.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |